There are clear challenges to achieving the eradication of chronic viral hepatitis in the Asia Pacific. These include preventing further transmission; ensuring that people infected with the virus are diagnosed and have access to clinical management for the condition; and ensuring that the health workforce has the skills and resources to respond to people with or at risk of the virus. CEVHAP’S key strategic focus is to improve public policy to change how viral hepatitis is managed across Asia Pacific. We will do this through

  • Advocacy – being an independent voice, connecting with other stakeholders, civil society and governments in calling for a better response to viral hepatitis
  • Policy Development - conducting evidence-based policy and associated research to address data gaps and inform the development of public policy
  • Education - building capacity at a local level by supporting
    local advocates with tools and knowledge to support their advocacy work

To access the CEVHAP Strategic Plan, click here

FaLang translation system by Faboba


>> CEVHAP Strategy 2017-2021



NOhep is a global, grassroots movement aimed at bringing all stakeholders together to eliminate viral hepatitis by 2030. It has been developed to create global awareness of the disease, similar to the red ribbon for HIV/AIDS, and was launched in 2016. NOhep firmly positions itself at the forefront of the elimination conversation, showcasing exemplary leadership, fostering on-the-ground innovative solutions and taking action to support the policy changes needed to eliminate this cancer-causing illness by 2030. Being a part of NOhep means being part of the solution. (To find out more about the development of this exciting initiative, watch this short video:

Viral Hepatitis
  Globally, 2 billion people have been
infected with hepatitis B virus, with an
estimated 600,000 dying each year . . .
  The number of people with chronic
hepatitis C and more advanced liver
disease or cirrhosis, is projected to
increase by 38% between 2006 and 2015
unless the number of people being
treated increases substantially.
  There is no vaccine for hepatitis C but
approximately 80% of patients who are
able to complete recommended
treatment, are cured . . .
Why hepatitis policy matters - the story of Baltazar Lucas  
Video What are the dangers of viral #hepatitis? Hear what #CEVHAP Chair Prof Ding-Shinn Chen had to say to the Wall Street Journal.
A Message from DS Chen
Chairman, CEVHAP


Connect with usconnect with CEVHAP